Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Oxaliplatin
Radiation: Short-course radiotherapy

First Posted Date: 2020-08-19

Last Posted Date: 2023-09-18

Lead Sponsor: Fudan University

Target Recruit Count: 130

Registration Number: NCT04518280

Locations: 🇨🇳
Shanghai Changhai Hospital, Shanghai, Shanghai, China
🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
🇨🇳
Zhen Zhang, Shanghai, Shanghai, China

and more 1 locations

A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients

Phase 2

Conditions: Central Nervous System Lymphoma

Interventions: Drug: chidamide combined with rituximab and high-dose methotrexate

First Posted Date: 2020-08-18

Last Posted Date: 2020-08-18

Lead Sponsor: Fudan University

Target Recruit Count: 51

Registration Number: NCT04516655

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Toripalimab
Radiation: IMRT to the nasopharynx and neck
Drug: Gemcitabine and Cisplatin Chemotherapy
Drug: Adjuvant chemotherapy with Capecitabine

First Posted Date: 2020-08-18

Last Posted Date: 2021-07-30

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT04517214

Locations: 🇨🇳
Xiaomin Ou, Shanghai, China

Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Eribulin,cisplatin
Drug: Gemcitabine,cisplatin

First Posted Date: 2020-08-18

Last Posted Date: 2020-08-18

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT04517292

Locations: 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China

Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer

Phase 3

Recruiting

Conditions: Colorectal Cancer
Vitamin C
GLUT3

Interventions: Drug: Ascorbic acid
Drug: FOLFOX Protocol
Drug: Adebrelimab

First Posted Date: 2020-08-18

Last Posted Date: 2024-10-24

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT04516681

Locations: 🇨🇳
Fudan university shanghai cancer center, Shanhai, Shanghai, China

Treatment After Palbociclib-containing Regimens

Completed

Conditions: Breast Cancer

First Posted Date: 2020-08-18

Last Posted Date: 2021-08-03

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04517318

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Not Applicable

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Durvalumab
Procedure: Transcatheter Hepatic Arterial Chemoembolization (TACE)
Procedure: Ablation

First Posted Date: 2020-08-18

Last Posted Date: 2021-05-03

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT04517227

Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Completed

Conditions: Breast Cancer

First Posted Date: 2020-08-18

Last Posted Date: 2021-06-18

Lead Sponsor: Fudan University

Target Recruit Count: 97

Registration Number: NCT04517305

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Phase 2

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: PD-1 antibody+ HDAC inhibitor

First Posted Date: 2020-08-13

Last Posted Date: 2024-11-11

Lead Sponsor: Fudan University

Target Recruit Count: 51

Registration Number: NCT04512534

Locations: 🇨🇳
Dongmei Ji, Shanghai, Shanghai, China

PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Phase 2

Conditions: Locally Advanced Gastric Adenocarcinoma
Metastatic Gastric Cancer

Interventions: Drug: Camrelizumab plus mFLOT regimen
Procedure: R0 surgery

First Posted Date: 2020-08-12

Last Posted Date: 2020-08-12

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT04510064

Locations: 🇨🇳
Fudan University, Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy